
1. clin res hepatol gastroenterol. 2017 dec;41(6):617-625. doi:
10.1016/j.clinre.2017.07.002. epub 2017 sep 4.

autoimmune hepatitis - update clinical management 2017.

liwinski t(1), schramm c(2).

author information: 
(1)i. department medicine, university medical center hamburg-eppendorf, 20251 
hamburg, germany. electronic address: t.liwinski@uke.de.
(2)i. department medicine, university medical center hamburg-eppendorf, 20251 
hamburg, germany; martin zeitz center rare diseases, university medical
center hamburg-eppendorf, hamburg, germany. electronic address: c.schramm@uke.de.

autoimmune hepatitis (aih) progressive immune mediated liver disease of
unknown origin. key diagnostic features include hypergammaglobulinemia/elevated
serum-igg, characteristic circulating autoantibodies, periportal hepatitis with
interface activity liver biopsy exclusion hepatotropic viruses.
however, diagnosis challenging cholestatic severe presentations. it
can difficult differentiate aih drug-induced liver injury. although
many patients initially respond standard immunosuppressive therapy, a
significant proportion experiences intolerable side effects insufficient
treatment response. underlines need effective alternative treatment 
options, still limited based rather poor evidence. this
review summarises core aspects clinical management aih focus on
recent achievements unmet needs.

copyright © 2017 elsevier masson sas. rights reserved.

doi: 10.1016/j.clinre.2017.07.002 
pmid: 28882739  [indexed medline]

